Platelet-rich Plasma in the Treatment of Intractable Postherpetic Neuralgia (NCT05444413) | Clinical Trial Compass
CompletedPhase 1
Platelet-rich Plasma in the Treatment of Intractable Postherpetic Neuralgia
China32 participantsStarted 2022-03-03
Plain-language summary
used ultrasound-guided platelet rich plasma nerve block to treat Intractable Postherpetic Neuralgia.
Who can participate
Age range40 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Meet the diagnostic criteria of PHN: have a history of acute herpes zoster, the pain lasts for more than half a year, and there is paroxysmal pain in the affected nerve distribution area;
* Preoperative visual analog scale (VAS) score ≥ 5;
* Those who can cooperate with the treatment;
* We agreed to inject platelet rich plasma into nerve block under the guidance of ultrasound, and signed the informed consent form.
Exclusion Criteria:
* Systemic infection or puncture local infection;
* Serious disturbance of cardiovascular and cerebrovascular function;
* Abnormal bleeding and coagulation function or complicated with blood system diseases;
* Mental disorders;
* Severe dysfunction of important organs in the body
What they're measuring
1
The changes from degree of pain that patients feel after the treatment are assessed by the numerical rating scale (NRS).
Timeframe: Change from the numerical rating scale at 6 months